Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib‐based treatment regimens

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|170|1|66-79

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.170, Iss.1, 2015-07, pp. : 66-79

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma

By  

Oncology, Vol. 85, Iss. 4, 2013-09 ,pp. : 223-227

Karger

Access to resources Recommend Favorite

LDH is an adverse prognostic factor independent of ISS in transplant‐eligible myeloma patients receiving bortezomib‐based induction regimens

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 4, 2015-04 ,pp. : 330-335

John Wiley & Sons Inc

Access to resources Recommend Favorite

Fatal Cytomegalovirus Pneumonia and Associated Herpes Virus Infection in a Relapsed/Refractory Multiple Myeloma Patient Treated with Bortezomib plus Dexamethasone

By  

Case Reports in Oncology, Vol. 2, Iss. 2, 2009-07 ,pp. : 140-143

Karger

Access to resources Recommend Favorite

Bortezomib‐based therapy combined with high cut‐off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 647-652

John Wiley & Sons Inc

Access to resources Recommend Favorite

Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature

By  

Acta Haematologica, Vol. 128, Iss. 4, 2012-09 ,pp. : 244-247

Karger

Access to resources Recommend Favorite